Key Takeaway: The FDA is seeking stakeholder input on robotic medical devices with autonomous or remote teleoperation capabilities. Developers of these technologies should consider how different degrees of autonomy and allocations of functionality between users and robotic systems affect patent strategy.
On November 6, 2026, the U.S. Food and Drug Administration (“FDA”) released a discussion paper seeking public feedback on the benefits and risks of robotic medical devices with autonomous or remote teleoperation capabilities. The paper is intended to facilitate early stakeholder input as the FDA considers these emerging technologies. The FDA stated that the paper is “intended for discussion purposes only and does not represent draft or final guidance,” and does not establish regulatory expectations.
The discussion paper follows the FDA’s September 2026 draft guidance, which addressed premarket submissions for certain robotically-assisted surgical devices. The draft guidance provided recommendations concerning non-clinical testing, clinical data, and labeling to support these premarket submissions, and was discussed in a previous Knobbe Medical blog post. The FDA’s new paper turns specifically to robotic medical devices with autonomous or remote teleoperation capabilities, including robotically-assisted surgical devices.
The FDA defines remote teleoperation as real-time remote access and control of a robotic device system “without the user being physically present in the room with the patient.” Autonomous capabilities, by contrast, allow a “robotic device system to perform tasks and make decisions based on [its] current state and sensing without user intervention.” According to the FDA, “[m]edical device manufacturers are exploring ways to utilize autonomous and/or remote teleoperation capabilities in robotic device systems in new healthcare applications.” Examples include remote ultrasound and surgery, autonomous peripheral blood draws, and robotic systems capable of autonomously detecting and controlling life-threatening internal bleeding.
The discussion paper includes 15 questions for stakeholders addressing several aspects of autonomous and remotely teleoperated robotic medical devices. The questions address, among other topics, terminology used to describe these systems, technical considerations associated with their operation, potential benefits and risks, and potential risk mitigations. The FDA intends to use stakeholder feedback to further its understanding of these emerging technologies and inform future policy development.
The FDA’s focus on autonomy, remote operation, and the allocation of functions between robotic systems and their users also has implications for patent strategy. As these technologies evolve, developers should consider whether patent claims adequately capture different degrees of autonomy and different allocations of functionality between users and the robotic systems. Additionally, technical solutions created to address regulatory considerations may themselves represent patentable innovations. Coordinating patent and regulatory strategies can help developers identify these innovations early and pursue patent protection as both the technology and regulatory framework advance.
The FDA’s Center for Devices and Radiological Health will hold a hybrid public workshop on December 2-3, 2026, to further discuss the issues raised in the discussion paper. Comments on the discussion paper may be submitted through January 5, 2027, under docket number FDA-2026-N-13135.